Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Duloxetine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 13/20 | 0.98 |
| ▸ | SLC6A4 known ✓ | P31645 | 13/20 | 0.98 |
| ▸ | SLC6A3 | Q01959 | 9/20 | 0.98 |
| ▸ | MLNR | O43193 | 1/20 | 0.98 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.98 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.98 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.98 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.98 |
| ▸ | HTR1A | P08908 | 1/20 | 0.98 |
| ▸ | GAA | P10253 | 1/20 | 0.98 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.98 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.98 |
| ▸ | DRD2 | P14416 | 1/20 | 0.98 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.98 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.98 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.98 |
| ▸ | HTR2A | P28223 | 1/20 | 0.98 |
| ▸ | HTR2C | P28335 | 1/20 | 0.98 |
| ▸ | MC4R | P32245 | 1/20 | 0.98 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Duloxetine SCHEMBL119403 | 1.00 | SLC6A2 (0.98) | SLC6A2SLC6A4SLC6A3MLNRCACNA1F | |
| Duloxetine SCHEMBL29389952 | 1.00 | SLC6A2 (0.98) | SLC6A2SLC6A4SLC6A3MLNRCACNA1F | |
| (R)-Duloxetine SCHEMBL3901869 | 1.00 | SLC6A2 (0.98) | SLC6A2SLC6A4SLC6A3MLNRCACNA1F | |
| Duloxetine SCHEMBL2384759 | 1.00 | SLC6A2 (0.98) | SLC6A2SLC6A4SLC6A3MLNRCACNA1F | |
| (R)-Duloxetine SCHEMBL30523711 | 1.00 | SLC6A2 (0.98) | SLC6A2SLC6A4SLC6A3MLNRCACNA1F | |
| Duloxetine SCHEMBL647773 | 1.00 | SLC6A2 (0.98) | SLC6A2SLC6A4SLC6A3MLNRCACNA1F | |
| Duloxetine SCHEMBL28196267 | 0.99 | SLC6A2 (0.95) | SLC6A2SLC6A4SLC6A3MLNRCACNA1F | |
| Duloxetine SCHEMBL3803 | 0.99 | SLC6A4 (1.00) | SLC6A2SLC6A4SLC6A3MLNRCACNA1F | |
| Duloxetine SCHEMBL10036575 | 0.99 | SLC6A4 (1.00) | SLC6A2SLC6A4SLC6A3MLNRCACNA1F | |
| Duloxetine SCHEMBL8291 | 0.99 | SLC6A4 (1.00) | SLC6A2SLC6A4SLC6A3MLNRCACNA1F |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2555 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122063214-A | Method for detecting N-nitrosoduloxetine in duloxetine hydrochloride bulk drug or preparation | 广东省药品检验所（广东省药品质量研究所、广东省口岸药品检验所） | 2026-05-19 | — | — | CN | claimed |
| US-12409139-B2 | Stable parenteral formulations of duloxetine | LEIUTIS PHARMACEUTICALS LLP (IN) | 2025-09-09 | — | — | US | claimed |
| US-20250205160-A1 | STABLE PHARMACEUTICAL COMPOSITION OF AN AMINE DRUG | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2025-06-26 | — | — | US | claimed |
| CN-113603673-B | Crystal form of duloxetine hydrochloride, preparation method and application thereof | 上海中西三维药业有限公司 | 2024-08-06 | — | — | CN | claimed |
| CN-118416002-A | Medicinal sugar pill with low friability and preparation method thereof | 杭州高成生物营养技术有限公司 | 2024-08-02 | — | — | CN | claimed |
| WO-2024117996-A1 | BIOEQUIVALENT ORAL PHARMACEUTICAL COMPOSITION COMPRISING DULOXETINE HYDROCHLORIDE | SANTA FARMA ILAC SANAYII A.S. (TR) | 2024-06-06 | — | — | WO | claimed |
| WO-2024015331-A1 | THERAPEUTIC AND DIAGNOSTIC METHODS FOR MULTIPLE SCLEROSIS | GENENTECH, INC. (US) | 2024-01-18 | — | — | WO | claimed |
| CN-116617189-B | Duloxetine hydrochloride sustained-release capsule and preparation method thereof | 四川尚锐生物医药有限公司 | 2023-09-26 | — | — | CN | claimed |
| CN-116617189-A | Duloxetine hydrochloride sustained-release capsule and preparation method thereof | 四川尚锐生物医药有限公司 | 2023-08-22 | — | — | CN | claimed |
| CN-116570587-A | Application of duloxetine hydrochloride in preparation of novel coronavirus resistant medicines | 中山大学·深圳 | 2023-08-11 | — | — | CN | claimed |
| EP-1273301-B1 | Pharmaceutical preparations based on active ingredients susceptible to illicit administration | ALTERGON SA (CH) | 2006-09-06 | — | — | EP | claimed |
| US-20060194869-A1 | Process for preparing pharmaceutically acceptable salts of duloxetine and intermediates thereof | TEVA PHARMACEUTICAL INDUSTRIES LTD (IL) | 2006-08-31 | — | — | US | claimed |
| WO-2006081515-A2 | DULOXETINE HYDROCHLORIDE POLYMORPHS | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2006-08-03 | — | — | WO | claimed |
| WO-2006071868-A2 | PROCESS FOR PREPARING PHARMACEUTICALLY ACCEPTABLE SALTS OF DULOXETINE AND INTERMEDIATES THEREOF | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2006-07-06 | — | — | WO | claimed |
| EP-1655029-A1 | MEDICINAL COMPOSITIONS | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2006-05-10 | — | — | EP | claimed |
| CN-1759829-A | Duloxetine enteric coated tiny pill capsule, and preparation method | SHANGHAI INST OF MEDICINE IND (CN) | 2006-04-19 | — | — | CN | claimed |
| CN-1747947-A | Process for preparing duloxetine and intermediates used therein | CIPLA LTD (IN) | 2006-03-15 | — | — | CN | claimed |
| WO-2005108386-A1 | CRYSTALLINE FORMS OF DULOXETINE FREE BASE | CIPLA LIMITED (IN) | 2005-11-17 | — | — | WO | claimed |
| WO-2005019199-A1 | AMORPHOUS DULOXETINE HYDROCHLORIDE | HETERO DRUGS LIMITED (IN) | 2005-03-03 | — | — | WO | claimed |
| EP-1273301-A2 | Pharmaceutical preparations based on active ingredients susceptible to illicit administration | ALTERGON S.A. (CH) | 2003-01-08 | — | — | EP | claimed |